EUVIMEDEUVIMED entdecken
Crossref

The third-generation EGFR TKI osimertinib could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC

Takahiro Karasaki

AME Clinical Trials Review · 2024

DOI: 10.21037/actr-23-33 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AME Clinical Trials Review, 2024. Verfasst von Takahiro Karasaki.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Karasaki, T. (2024). The third-generation EGFR TKI osimertinib could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC. AME Clinical Trials Review. https://doi.org/10.21037/actr-23-33

Vancouver

Karasaki T. The third-generation EGFR TKI osimertinib could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC. AME Clinical Trials Review. 2024. doi:10.21037/actr-23-33

BibTeX
@article{Karasaki2024,
  author = {Karasaki, Takahiro},
  title = {The third-generation EGFR TKI osimertinib could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC},
  journal = {AME Clinical Trials Review},
  year = {2024},
  doi = {10.21037/actr-23-33}
}
Kostenlos starten →